News - Tysabri


Current filters:


Popular Filters

Elan board agrees $8.6 billion takeover bid


US health care company Perrigo (NYSE: PRGO) revealed this morning that Ireland-based drugmaker Elan Corp…

ElanGenericsMergers & AcquisitionsPerrigoPharmaceuticalTysabri

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch


US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Elan posts financials, as it explores sale of the company


Ireland-based Elan Corp (NYSE:ELN) today reported its second quarter 2013 financial results, showing…

ElanFinancialMergers & AcquisitionsPharmaceuticalTysabri

Royalty Pharma hikes offer for Elan to $13 a share, plus CVR of up to $2.50


Ireland-based Elan Corp (NYSE: ELN) saw its shares to 5.3% to $13.35 by mid morning last Friday (June…

ElanMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer


In the ongoing saga of Royalty Pharma's takeover attempts, Ireland-based Elan (NYSE: ELN) has communicated…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan reports 1st-qtr operating loss


Ireland-based Elan Corp (NYSE: ELN), which has again rejected takeover approach form Royalty Pharma and…


Elan to unlock benefits for shareholders from Tysabri deal


The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan plans $1 billion repurchase program post Tysabri deal closure


Ireland-headquartered drugmaker Elan Corp (NYSE: ELN) disclosed its deployment plans for the $3.25 billion…


Elan sells its Tysabri rights to Biogen; posts 2012 financials


Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

New analysis of risk stratification for Biogen and Elan's Tysabri


US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

Elan back in the black, boosted by Tysabri


Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…


FDA updates Tysabri label relating to anti-JCV


The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

EU clears anti-JC virus risk labeling for Biogen and Elan’s Tysabri


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan (NYSE: ELN) said yesterday that the…

Biogen IdecBiotechnologyElanEuropeNeurologicalRegulationTysabri

Biogen Idec shares leap, as 1st-qtr 2011 earnings rocket, boosted by Tysabri; and by MS drug results


Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) soared 20% to $104.11 in pre-market trading last…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTysabri

Back to top